UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

Medications for myasthenia gravis (MG ... Eculizumab helps prevent neuromuscular junction damage. You’ll receive it weekly for 4 weeks, followed by every 2 weeks, and is approved for people ...

It only took six minutes during Thursday night’s Trigg County Schools Board of Education meeting. But in the end, a trio of ...

Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction that causes fatigable neuromuscular weakness. 85% of patients have antibodies against the acetylcholine receptor (AChR) ...

If the condition involves neuromuscular junctions, atypical myasthenia gravis (MG) or Lambert-Eaton syndrome should ... indicating neuromuscular junction (NMJ) blockade. Low-frequency (3Hz) repetitive ...

Large-scale studies are needed to confirm these findings. Myasthenia gravis (MG) is an autoimmune disease affecting the neuromuscular junction; it is primarily caused by the production of ...

argenx is solidifying its leadership in FcRn biology with efgartigimod, complement inhibition with empasiprubart and in the role of MuSK at the neuromuscular junction with ARGX-119. In 2025, argenx ...

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...